anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Within the continuum of consciousness, patients in a Minimally Conscious State (MCS) may exhibit high-level behavioral responses (MCS+) or may not (MCS-). The evaluation of residual consciousness and related classification is crucial to propose tailored rehabilitation and pharmacological treatments, considering the inherent differences among groups in diagnosis and prognosis. Currently, differential diagnosis relies on behavioral assessments posing a relevant risk of misdiagnosis. In this context, EEG offers a non-invasive approach to model the brain as a complex network. The search for discriminating features could reveal whether behavioral responses in post-comatose patients have a defined physiological background. Additionally, it is essential to determine whether the standard behavioral assessment for quantifying responsiveness holds physiological significance.
METHODS: In this prospective observational study, we investigated whether low-density EEG-based graph metrics could discriminate MCS+/- patients by enrolling 57 MCS patients (MCS-: 30; males: 28). At admission to intensive rehabilitation, 30 min resting-state closed-eyes EEG recordings were performed together with consciousness diagnosis following international guidelines. After EEG preprocessing, graphs' metrics were estimated using different connectivity measures, at multiple connection densities and frequency bands (α,θ,δ). Metrics were also provided to cross-validated Machine Learning (ML) models with outcome MCS+/-.
RESULTS: A lower level of brain activity integration was found in the MCS- group in the α band. Instead, in the δ band MCS- group presented an higher level of clustering (weighted clustering coefficient) respect to MCS+. The best-performing solution in discriminating MCS+/- through the use of ML was an Elastic-Net regularized logistic regression with a cross-validation accuracy of 79% (sensitivity and specificity of 74% and 85% respectively).
CONCLUSION: Despite tackling the MCS+/- differential diagnosis is highly challenging, a daily-routine low-density EEG might allow to differentiate across these differently responsive brain networks.
SIGNIFICANCE: Graph-theoretical features are shown to discriminate between these two neurophysiologically similar conditions, and may thus support the clinical diagnosis.
The invention discloses a preparation method of a milk safety capsule. Prior to preparation, medical herbs are sterilized by reducing the pressure of ethanol gas, and the traditional Chinese medicine can be sterilized at low temperature (below 80 DEG C) without destroying effective ingredients of the traditional Chinese medicine. The applied granulation method is a one-step granulation method with integration of mixing, granulation and drying. During granulation, the air temperature is 85-95 DEG C, the exhaust temperature is 45-55 DEG C, the temperature of materials is 50-60 DEG C, the material retention time is 2-3 hours, the spraying frequency is 5-8Hz, and the moisture content in particles is less than 2.0 percent. By adopting the preparation method, the working hours can be saved, and the production efficiency can be improved; and the heating time of the medical herbs can be reduced, the loss of effective ingredients can be decreased, and the product quality can be improved indirectly. The medicine is made into grains and the grains are filled in capsules, so the workshop can be prevented from being polluted by flying dust when the medical powder is filled in the capsules, the preparation method is conducive to the fluidity of the powder, and the filling amount of the capsules can be controlled easily.
A 'qingmei' cold granule formula capable of clearing heat and relieving exterior syndrome and a preparing method thereof are disclosed. The formula comprises following components: 200 g of sweet wormwood, 267 g of citrus medica sarcodactylis, 134 g of herba elsholtziae, 200 g of herb of Chinese dicliptera, 134 g of licorice, 134 g of centella, 267 g of holly root and 867 g of cane sugar, and the components are prepared into 1000 g of the cold granules. According to the cold granules, seven active components have significant curative effects for wind-heat type cold. All the components act in combination, so that the granules suit the remedy to the case for the patients. The granules are highly targeted, short in treating time, and definite and significant in curative effects. The granules can enrich the market medicine variety so as to meet and guarantee medicine needs of people. The granules are simple in production process, convenient in manufacturing, and low in cost. By the preparing method, the granules which are capable of suiting the remedy to the case, highly targeted, quick-acting, definite and significant in curative effects, convenient in manufacturing and low in cost and are used for treating wind-heat type cold is obtained.
As a multi system granulomatous disease, clinical presentations of sarcoidosis are highly variable. In the absence of a stereotypical clinical presentation such as asymptomatic bilateral hilar adenopathy, Lofgren's syndrome, or lupus pernio, a diagnosis of sarcoidosis typically requires 1) compatible clinical presentation, 2) histologic evidence of granulomatous inflammation, and 3) the exclusion of other causes. The clinical presentation of sarcoidosis is often nonspecific and a variety of other causes of granulomatous inflammation can make diagnosing sarcoidosis a challenge for clinicians. "Overlap syndromes" are often used to describe clinical presentations of sarcoidosis that share histologic and clinical features of other diseases, or when the diagnosis of sarcoidosis is made in association with the coexistence of another diagnosis with similar clinical or histologic findings. Because of the risk of diagnostic delay and diagnostic errors, it is vital for clinicians to be familiar with overlap syndromes in sarcoidosis. The coexistence of sarcoidosis with other diseases can also significantly impact disease management and outcomes. This article will review the most current published data on overlap syndromes in sarcoidosis to aid clinicians in diagnosing and managing these complex patients.
PURPOSE:To use 1,5-benzothiazepine compounds, 1,6-benzothiazocine compounds, or their acid addition salts, as an antiulcer agent taking advantage of its strong effect to suppress the secretion of gastric juice. CONSTITUTION:The compound of formula (R is H or CHO; n is 3 or 4) or its acid addition salt is used as an antiulcer agent. The compound of formula is 1,5-benzothiazepine compound when n is 3, and 1,6-benzothiazocine compound when n is 4. It has been found that both of them have strong activity to suppress the secretion of gastric juice. The compound suppresses the pH, the secretion of juice, and the secretion of acid in the stomach, and is useful as an antiulcer agent. Concrete examples of the compound of formula are 1,6-benzothiazocine, 1,5-benzothiazepine hydrochloride, etc. Dose; 5-75mg per dose for adult by oral administration, 3-4 doses daily.
All patients will be treated in a single session approach regardless of the group. All molars will be anesthetized either through infiltration in case of maxillary molars or inferior alveolar nerve block in case of mandibular molars using Octocaine 2% with epinephrine 1: 100,000 (Lidocaine HCl, Novocol Pharmaceutical, Ontario, Canada.). Rubber dam will be applied; and access will be opened using Endo access bur.

In group A manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. In group B glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone. Root canals will be copiously irrigated using 10 ml 2.5% sodium hypochlorite NaOCl (Clorox; Egyptian Company for household bleach, Egypt) delivered using 28 Gauge safety Steri Irrigation Tip (DiaDent Group International, Burnaby, BC, Canada) inserted 3 mm below cementoenamel junction. Working length will be determined using electronic apex locator Root ZX II (J. Morita Mfg. Corp, Kyoto, Japan) and confirmed radiographically using parallel technique with receptor holding device. Canals were irrigated again with 10ml 1.5% NaOCl, which was delivered 2mm coronal to apical canal terminus. Irrigation was hydro-dynamically agitated with EndoActivator device (Dentsply Maillefer, Baillagues, Switzerland) using blue tips #30/06 inserted 2mm short of working length for 60 seconds. Root canals will be shaped using ProTaper next rotary Ni-Ti files (Dentsply Maillefer, Baillagues, Switzerland). Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
<P>PROBLEM TO BE SOLVED: To provide a composition that sufficiently suppresses a peculiar unpleasant odor of component in spite of containing a pearl protein extract, a yeast extract or a hydrolyzed collagen.  <P>SOLUTION: The composition includes at least one selected from the group consisting of a pearl protein extract, a yeast extract and a hydrolyzed collagen and an extract of a plant (e.g. Psophocarpus tetragonolobus) of the genus Psophocarpus of the family Leguminosae. The composition sufficiently suppresses a peculiar unpleasant odor of component in spite of containing a compound such as a pearl protein extract, a yeast extract or a hydrolyzed collagen having a peculiar unpleasant odor since the composition contains the extract of the plant of the genus Psophocarpus of the family Leguminosae. Therefore, the composition is suitable for a cosmetic or a food and beverage.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A method for volumetric segmentation in a plurality of planar medical images includes, receiving, at an electronic processor, the plurality of planar medical images. A boundary of a candidate structure in the plurality of medical images is generated using a segmentation model. A first planar medical image from the plurality of planar medical images is displayed on a display. A user input is received using a user interface indicating a region in the first planar medical image. A first planar contour of the candidate structure is generated. The region is compared to the boundary. Responsive to the region being at least partially within the boundary, the first planar medical image is re-displayed on the display showing the first planar contour of the structure, and a finding record for the candidate structure including the boundary is generated.
Systems and methods are disclosed for a medical pill dispensing system. A system includes a plurality of canisters and/or a manual fill tray for storing one or more pills, where the supply module includes a plurality of containers. Each of the plurality of containers or the manual fill tray is configured to dispense one or more pills of a respective type. The system also includes a hopper system for receiving the one or more pills from the plurality of containers or the manual fill tray. The system also includes a top pre-fill tray configured to receive one or more pills from the hopper system. The system further includes a bottom pre-fill tray configured to receive one or more pills from the top pre-fill tray. Both the top pre-fill tray and the bottom pre-fill tray include a plurality of X-direction and Y-direction pointers. The system also includes a control module that facilitates alignment of the top pre-fill tray with the bottom pre-fill tray using the X-direction and Y-direction pointers in both the top pre-fill tray and the bottom pre-fill tray. Feedback logic is used by the control module to align then top and bottom pre-fill trays. The system also includes a packing plate that is capable of receiving a plurality of pill packs. In operation, the system controls dispensing and navigation of one or more pills from a container or manual pre-fill tray such that the pill makes it way from the container, through the hopper system and the top and bottom pre-fill trays and into a desired slot in the pill pack. The multi pre-fill tray system, and its mechanisms that provide for separated compartmentalization of pills, allow the medical pill dispensing system to parallel process and dispense pills designated for multiple pill packs without having to wait till the completion of any one pill pack thereby providing for a higher efficiency system while ensuring that pills designated for one pill pack are not mixed with pills designated for another pill pack.
The invention is directed to a biodegradable implant precursor having a two-part structure made of an outer sac and a liquid content. The implant precursor is composed of a biodegradable, water-coagulable thermoplastic polymer and a water-miscible organic solvent. When administered to an implant site in an animal, the implant precursor will solidify in situ to a solid, microporous matrix by dissipation of the organic solvent to surrounding tissue fluids and coagulation of the polymer. The invention also includes methods of making the implant precursor, an apparatus for forming the precursor, and a kit containing the apparatus. Also provided are methods of using the implant precursor for treating a tissue defect in an animal, for example, for enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like, for delivery of biologically-active substances to tissue or organs, and other like therapies. <IMAGE>
Pro-inflammatory macrophages (M1-polarized) play a crucial role in neuroinflammation and neuropathic pain following nerve injury. Redirecting macrophage polarization toward anti-inflammatory (M2-polarized) phenotypes offers a promising therapeutic strategy. Recognized for their anti-inflammatory and immunomodulatory properties, probiotics are becoming a focal point of research. This study investigated the effects of Lactobacillus plantarum on macrophage polarization, nerve protection, and neuropathic pain behavior following chronic constriction injury (CCI) of the median nerve. Rats received daily oral doses of L. plantarum for 28 days before and 14 days after CCI. Subsequently, behavioral and electrophysiological assessments were performed. The M1 marker CD86 levels, M2 marker CD206 levels, and concentrations of pro-inflammatory and anti-inflammatory cytokines in the injured median nerve were assessed. L. plantarum administration effectively reduced neuropathic pain behavior and the Firmicutes to Bacteroidetes ratio after CCI. Moreover, L. plantarum treatment increased serum short-chain fatty acids (SCFAs) levels, preserved myelination of the injured median nerve, and suppressed injury-induced discharges. In CCI rats treated with L. plantarum, there was a reduction in CD86 and pro-inflammatory cytokine levels, accompanied by an increase in CD206 and the release of anti-inflammatory cytokines. Furthermore, receptors for anti-inflammatory cytokines were localized on Schwann cells, and their expression was significantly upregulated in the injured nerves of CCI rats receiving L. plantarum. In conclusion, L. plantarum shifts macrophage phenotypes from M1 to M2 by promoting the production of SCFAs and enhancing the release of anti-inflammatory cytokines. Ultimately, this process preserves nerve fiber integrity and impedes the onset of neuropathic pain.
Simultaneous inhibition of angiotensin II AT1 and endothelin ETA receptors has emerged as a promising approach for treatment of chronic progressive kidney disease. This therapeutic approach has been advanced by the introduction of sparsentan, the first dual AT1 and ETA receptor antagonist. Sparsentan is a single molecule with high affinity for both receptors. It is US Food and Drug Administration approved for immunoglobulin A nephropathy (IgAN) and is currently being developed as a treatment for rare kidney diseases, such as focal segmental glomerulosclerosis. Clinical studies have demonstrated the efficacy and safety of sparsentan in these conditions. In parallel with clinical development, studies have been conducted to elucidate the mechanisms of action of sparsentan and its position in the context of published evidence characterizing the nephroprotective effects of dual ETA and AT1 receptor inhibition. This review summarizes this evidence, documenting beneficial anti-inflammatory, antifibrotic, and hemodynamic actions of sparsentan in the kidney and protective actions in glomerular endothelial cells, mesangial cells, the tubulointerstitium, and podocytes, thus providing the rationale for the use of sparsentan as therapy for focal segmental glomerulosclerosis and IgAN and suggesting potential benefits in other renal diseases, such as Alport syndrome.
Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.
Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition) during facility study period 1, followed by a wash-out period, during which several patients are expected to be discharged and new patients are expected to be admitted. In facility study period 2, all consenting MDRO-positive patients (i.e. control condition) will observed with weekly sampling during study period 2.
Low-voltage-gated calcium channels (LVGCCs; Cav 3.1-3.3) represent promising drug targets for epilepsy, pain, and essential tremor. At present, modulators with heightened selectivity for a subtype of LVGCCs are still highly desired. In this study we explored three classes of Buxus alkaloids and identified 9(10/19)abeo-artanes Buxusemine H and Buxusemine L (BXSL) as an unprecedented type of Cav 3.2 inhibitors. Particularly, BXSL exhibited Cav 3.2 inhibition comparable to Z944, a non-subtype-selective LVGCCs inhibitor under clinical trial. While lacking specificity for Cav 3.3, BXSL showed a 30-fold selectivity of Cav 3.2 over Cav 3.1. As compared to several well-known inhibitors, the experimental and computational studies suggested BXSL exhibits a distinct binding mode to Cav 3.2, notably through the essential interaction with serine-1543 in domain III. Furthermore, BXSL showed minimal impact on various recombinant and native nociceptive ion channels, while significantly reducing the excitability of isolated mouse dorsal root ganglion neurons. Animal studies in wild-type and Cav 3.2 knock-out mice revealed that BXSL (5 mg/kg), by inhibiting Cav 3.2, exhibits an analgesic effect equivalent to Z944 (10 mg/kg) or mibefradil (10 mg/kg). Moreover, we proposed a structural rationale for the high selectivity of 9(10/19)abeo-artane-type alkaloids towards Cav 3.2 over Cav 3.1. This study introduces a novel analgesic agent and valuable molecular insight for structure-based innovative Cav 3.2 drug development.
INTRODUCTION: Children with intellectual disability (ID) often face challenges in maintaining proper oral hygiene due to their motor, sensory, and intellectual impairments, which can lead to compromised oral health; therefore, there is a need to enhance the oral health status of these populations and establish an effective system for administering preventive interventions. Here, we aimed to evaluate the prevalence of Entamoeba gingivalis and Trichomonas tenax among children with ID in Lorestan province, in Western Iran through parasitological and molecular methods.
METHODS: The current descriptive investigation involved 215 in children with ID and 215 healthy children (non-ID) who were referred to health facilities in Lorestan province, Iran between October 2022 and March 2024. The prevalence of protozoa in the oral cavity was found through the utilization of both microscopic analysis and conventional polymerase chain reaction (PCR) techniques.
RESULTS: The total prevalence of the E. gingivalis and T. tenax in children with ID was found to be 87 (40.5%) and 92 (42.8%) through microscopic and PCR methods, respectively. Among the positive samples, 57 (61.9%) and 35 (38.1%) children tested positive for E. gingivalis and T. tenax, respectively. In contrast, among the 215 non-ID children in the control group, 39 (18.1%) and 42 (19.5%) tested positive by microscopic and PCR methods, respectively. Among positive samples in non-ID children, 23 (54.7%) and 19 (45.3%) children were positive for E. gingivalis and T. tenax, respectively. Multiple logistic regression analysis indicated that residing in urban areas, parental education, monthly family income, and tooth brushing p<0.001) were identified as independent risk factors for oral cavity parasites.
CONCLUSION: This study identified a notable prevalence of oral cavity parasites in children with ID in Lorestan province, Western Iran. It is imperative to recognize the primary risk factors associated with these parasites, particularly inadequate teeth brushing, in order to enhance public and oral health strategies for children with ID. Therefore, pediatric dental professionals should remain vigilant regarding these risk factors to effectively recognize and address oral health issues in this population, thereby mitigating the occurrence of oral diseases and infections.
The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium 0.6mg/kg. Anesthesia will be maintained using isofluorane through volume controlled ventilation, and a mixture of magnesium sulfate 40mg/kg (without exceeding 2.5g/24h), lidocaine 1.5mg/kg, ketamine 25mg, and clonidine 1ug/kg in an electric pump syringe at 10 - 15 ml/h.
A sleeping state improvement system and a sleeping state improvement method capable of improving a sleeping state of a user even when the user sleeps away from home are provided. A sleeping state improvement system (1) is a sleeping state improvement system to improve a sleeping state of a user (P), comprising a memory member (70) and a control device (30) that comprises a specification unit (31) and a control unit (32). The memory member (70) can be carried by the user (P). The specification unit (31) specifies individual attribute information of the user (P) based on individual information. The individual information is information stored in the memory member (70). The control unit (32) controls an environment during sleep of the user (P) based on the individual attribute information.
The invention belongs to the technical field of biology, and particularly relates to a hyaluronic acid lyase, a gene thereof, a recombinant vector and a cell containing the gene, and expression and application of the hyaluronic acid lyase. A hyaluronan lyase, wherein the amino acid sequence of the hyaluronan lyase is shown as SEQ ID No. 1. A hyaluronic acid lyase gene codes hyaluronic acid lyase, and the sequence is a sequence shown in SEQ ID NO.2 or a complementary sequence of SEQ ID NO. 2. According to the invention, the heterologous high-efficiency active expression of the bacterial hyaluronic acid lyase is successfully realized by adopting an engineering strain (escherichia coli or bacillus subtilis) expression system, the fermentation activity is obviously higher than that of the prior report, the large-scale production of the bacterial hyaluronic acid lyase is realized, the defect that the separation and purification process of a wild strain is complex is overcome, and the high-purity hyaluronic acid lyase product is prepared, so that a foundation is laid for the industrial production of the hyaluronic acid lyase and the research and application of the hyaluronic acid lyase in the fields of biochemical engineering, medicines and the like.
Wide-field OCT was performed 1-2 weeks before the trabeculectomy. The OCT was done postoperatively at 1 month, 3 months, 6 months and 12 months after surgery.